Curis INC Form 4 insider transactions

Curis Inc. Director Marc Rubin was granted 6,800 stock options with an exercise price of $5.29, vesting fully on July 7, 2027.

Curis Inc. Director Kenneth I. Kaitin has been granted 6,800 non-qualified stock options with an exercise price of $5.29, vesting fully on July 7, 2027.

Curis Inc. director John Hohneker has been granted a non-qualified stock option for 6,800 shares with an exercise price of $5.29, vesting fully on July 7, 2027.

Curis Inc. Director Martyn D. Greenacre was granted stock options for 6,800 shares of common stock.

Curis Inc. Director Anne Elizabeth Borgman acquired 6,800 stock options with an exercise price of $5.29, vesting fully on July 7, 2027.

Diantha Duvall, CFO of Curis Inc., was granted 48,285 employee stock options with an exercise price of $5.29.

Curis Inc. reports that CDO Jonathan B. Zung was granted employee stock options for 48,285 shares at an exercise price of $5.29.

Curis Inc. President & CEO James E. Dentzer reports a stock option grant for 110,090 shares with an exercise price of $5.29.

Curis Inc. Director Kenneth I. Kaitin plans to acquire 10,000 shares of common stock at $0.5487 per share on March 31, 2026, under a Rule 10b5-1 plan.

Curis Inc.'s Chief Development Officer, Jonathan B. Zung, converted 50 shares of Series B Convertible Preferred Stock into 66,667 shares of common stock.

CURIS's Chief Medical Officer, Dr. Ahmed Hamdy, converted 50 shares of Series B Convertible Preferred Stock into 66,667 shares of common stock on March 20, 2026.

Curis Inc.'s CFO, Diantha Duvall, converted 50 shares of Series B Convertible Preferred Stock into 66,666 shares of common stock.

CURIS Inc.'s President and CEO, James E. Dentzer, converted 100 shares of Series B Convertible Preferred Stock into 133,333 shares of common stock.

Curis Inc. Director Marc Rubin converted 20 shares of Series B Convertible Preferred Stock into 26,667 shares of common stock on March 20, 2026.

Curis Inc.'s Chief Development Officer, Jonathan B. Zung, has acquired Series B Convertible Preferred Stock and associated warrants, signaling increased insider ownership.

CURIS's Chief Medical Officer, Ahmed Hamdy MD, acquired Series B Convertible Preferred Stock and associated warrants, signaling increased insider ownership.

CURIS CFO Diantha Duvall reported the acquisition of convertible preferred stock and associated warrants, signaling potential future common stock ownership.

Curis Inc.'s President and CEO, James E. Dentzer, acquired Series B Convertible Preferred Stock and associated warrants, signaling increased insider ownership.

Curis Inc. Director Marc Rubin acquired Series B Convertible Preferred Stock and three series of warrants, totaling significant potential common stock ownership, as part of a $1,000 per security package.

James E. Dentzer, President & CEO of Curis Inc., reports the acquisition of stock options following shareholder approval of an amendment to the company's stock incentive plan.

Director John Hohneker receives a stock option grant for 14,400 shares of Curis Inc. following shareholder approval of Amendment No. 1 to the Fifth Amended and Restated 2010 Stock Incentive Plan.

Director Martyn D. Greenacre reports the acquisition of stock options in Curis Inc. following shareholder approval of an amendment to the company's stock incentive plan.

Director Marc Rubin acquired options for 14,400 shares of Curis Inc. stock after shareholders approved an amendment to the company's stock incentive plan.

Diantha Duvall, CFO of Curis Inc., reports the grant of a stock option for 135,000 shares of common stock at an exercise price of $3.13, vesting quarterly until January 2029.

Director Anne Elizabeth Borgman reports acquisition of 14,400 stock options in Curis Inc. following shareholder approval of Amendment No. 1 to the Fifth Amended and Restated 2010 Stock Incentive Plan.

Jonathan B. Zung, Chief Development Officer of Curis Inc., reports the acquisition of a stock option grant for 135,000 shares of common stock.

Director Kenneth Kaitin reports the acquisition of stock options in Curis Inc. following shareholder approval of an amendment to the company's stock incentive plan.

Ahmed Hamdy, CMO of Curis Inc., reports the acquisition of 200,000 employee stock options with an exercise price of $2.48, vesting over four years.

Diantha Duvall, CFO of Curis Inc., reports the acquisition of stock options in the company.

James E. Dentzer, President and CEO of Curis Inc., reports the acquisition of stock options.